Heart failure with improved ejection fraction: Is a newcomer in the family important?

Abstract

Get full access to this article

View all access options for this article.

References

Yancy

Jessup

Bozkurt

et al.

2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 128: 1810–1852.

Wilcox

Yancy

. Heart failure–a new phenotype emerges. JAMA Cardiol 2016; 5: 507–509.

Kalogeropoulos

Fonarow

Georgiopoulou

et al.

Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction. JAMA Cardiol 2016; 1: 510–518.

Bax

Poldermans

Elhendy

et al.

Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography. JACC 1999; 34: 163–169.

Stevenson

. Heart failure with better ejection fraction a modern diagnosis. Circulation 2014; 129: 2364–2367.

Florea

Rector

Anand

et al.

Heart failure with improved ejection fraction: Clinical characteristics, correlates of recovery, and survival. Results from the Valsartan Heart Failure Trial. Circ Heart Fail 2016; 9. (7). doi: 10.1161/CIRCHEARTFAILURE.116.003123.

Basuray

French

et al.

Heart failure with recovered ejection fraction: Clinical description, biomarkers, and outcomes. Circulation 2014; 129: 2380–2387.

Joergensen

et al.

Characteristics and prognosis of heart failure with improved compared with persistently reduced ejection fraction – A systematic review and meta-analyses. Eur J Prev Cardiol 2018; 25: 366–376.

Konstam

Rousseau

Kronenberg

et al.

Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure: SOLVD Investigators. Circulation 1992; 86: 431–438.

10.

Packer

Colucci

Sackner-Bernstein

et al.

PRECISE Study Group. Double-blind placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The PRECISE trial: Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996; 94: 2793–2799.

11.

St John Sutton

Plappert

Abraham

et al.

Multicenter InSync Randomized Clinical Evaluation (MIRACLE) Study Group. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 2003; 107: 1985–1990.

12.

Bax

Poldermans

Elhendy

et al.

13.

Boehmer

Starling

Cooper

et al.

IMAC Investigators. Left ventricular assist device support and myocardial recovery in recent onset cardiomyopathy. J Card Fail 2012; 18: 755–761.

14.

Drakos

Wever-Pinzon

Selzman

et al.

UCAR (Utah Cardiac Recovery Program) Investigators. Magnitude and time course of changes induced by continuous-flow left ventricular assist device unloading in chronic heart failure: Insights into cardiac recovery. J Am Coll Cardiol 2013; 61: 1985–1994.

15.

Steimle

Stevenson

Fonarow

et al.

Prediction of improvement in recent onset cardiomyopathy after referral for heart transplantation. J Am Coll Cardiol 1994; 23: 553–559.

16.

Sliwa

Hilfiker-Kleiner

Petrie

et al.

Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: A position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010; 12: 767–778.

17.

Steimle

Stevenson

Fonarow

et al.

Prediction of improvement in recent onset cardiomyopathy after referral for heart transplantation. J Am Coll Cardiol 1994; 23: 553–559.

18.

Moon

Chung

et al.

Recovery and recurrence of left ventricular systolic dysfunction in patients with idiopathic dilated cardiomyopathy. Can J Cardiol 2009; 25: e147–e150.

19.

Teeter

Thibodeau

Rao

et al.

The natural history of new-onset heart failure with a severely depressed left ventricular ejection fraction: Implications for timing of implantable cardioverter-defibrillator implantation. Am Heart J 2012; 164: 358–364.

20.

McNamara

Starling

Cooper

et al.

IMAC Investigators. Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: Results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study. J Am Coll Cardiol 2011; 58: 1112–1118.

21.

Wilcox

Fonarow

Yancy

et al.

Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: Findings from IMPROVE HF. Am Heart J 2012; 163: 49–56. e2.

22.

Punnoose

Givertz

Lewis

et al.

Heart failure with recovered ejection fraction: A distinct clinical entity. J Card Fail 2011; 17: 527–532.

23.

Agra Bermejo R, Gonzalez Babarro E, López Canoa JN, et al. Heart failure with recovered ejection fraction: Clinical characteristics, determinants and prognosis. CARDIOCHUS-CHOP registry. Cardiol J. Epublished ahead of print 5 October 2017. DOI: 10.5603/CJ.a2017.0103.

24.

Bruckner

Razeghi

Stetson

et al.

Degree of cardiac fibrosis and hypertrophy at time of implantation predicts myocardial improvement during left ventricular assist device support. J Heart Lung Transplant 2004; 23: 36–42.

25.

Ponikowski

Voors

Anker

et al.

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129–2200.

26.

Moon

Chung

et al.

Recovery and recurrence of left ventricular systolic dysfunction inpatients with idiopathic dilated cardiomyopathy. Can J Cardiol 2009; 25: e147–e150.

27.

Waagstein

Caidahl

Wallentin

et al.

Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989; 80: 551–563.

28.

Ruwald

Solomon

Foster

et al.

Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: Results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial. Circulation 2014; 130: 2278–2286.